Synthetic lethality-based targets for discovery of new cancer therapeutics

Cancer Genomics and Proteomics

Volumn 8, Issue 4, 2011, Pages 159-171

  Weidle, Ulrich H ^a   Maisel, Daniela ^a   Eick, Dirk ^b  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

DNA repair; Oncogenes; Poly(ADP) ribose polymerase; Protein kinase networks; Review; Tumor suppressor genes

Indexed keywords

BORTEZOMIB; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE 4; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; K RAS PROTEIN; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN KINASE; RAD51 PROTEIN; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TEMSIROLIMUS; TOZASERTIB; VON HIPPEL LINDAU PROTEIN;

BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; DNA DAMAGE; DNA REPAIR; DRUG TARGETING; GENE EXPRESSION; HUMAN; HYPOXIA; LETHALITY; LOSS OF FUNCTION MUTATION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; REVIEW; SYNTHETIC LETHALITY; TUMOR SUPPRESSOR GENE;

EID: 79960469668     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Lord CJ and Ashworth A: Biology-driven cancer drug development: back to the future. BMC Biol 8: 38, 2010.
2. Melo JV and Deininger MW: Biology of chronic myelogenous leukemia - signaling pathways of initiation and transformation. Hematol Oncol Clin North Am 18: 545-568, 2004. (Pubitemid 38969131)
3. Zhang J, Yang PL and Gray NS: Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39, 2009.
4. Gerber DE and Minna JD: ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 18: 548-551, 2010.
5. Tucker CL and Fields S: Lethal combinations. Nat Genet 35: 204-205, 2003. (Pubitemid 37363168)
6. Hartwell LH, Szankasi P, Roberts CJ, Murray AW and Friend SH: Integrating genetic approaches into the discovery of anticancer drugs. Science 275: 1064-1068, 1997. (Pubitemid 27517876)
7. Simon JA, Szankasi P, Nguyen DK, Ludlow C, Dunstan HM, Roberts CJ, Jensen EL and Hartwell LH and Friend SH: Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res 60: 328-333, 2000. (Pubitemid 30070759)
8. Kaelin WG Jr.: The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5: 689-698, 2005.
9. Kaelin WG Jr.: Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med 1: 99, 2009.
10. Ferrari E, Lucca C and Foiani M: A lethal combination for cancer cells: synthetic lethality screenings for drug discovery. Eur J Cancer 46: 2889-2895, 2010.
11. Mizuarai S and Kotani H: Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Hum Genet 128: 567-575, 2010.
12. Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC and Gilliland DG: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137: 821-834, 2009.
13. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK and Elledge SJ: A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835-848, 2009.
14. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T and Hahn WC: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462: 108-112, 2009.
15. Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, Guerra C, Santamaría D and Barbacid M: A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18: 63-73, 2010.
16. Zhu T, Chen L, Du W, Tsuji T and Chen C: Synthetic lethality induced by loss of PKC δ and mutated Ras. Genes Cancer 1: 142-151, 2010.
17. Torrance CJ, Agrawal V, Vogelstein B and Kinzler KW: Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 19: 940-945, 2001. (Pubitemid 32947572)
18. Wang Y, Ngo VN, Marani M, Yang Y, Wright G, Staudt LM and Downward J: Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 29: 4658-4670, 2010.
19. Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22, 2003.
20. Maslon MM and Hupp TR: Drug discovery and mutant p53. Trends Cell Biol 20: 542-555, 2010.
21. Brosh R and Rotter V: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9: 701-713, 2009.
22. Staples OD, Steele RJ and Lain S: p53 as a therapeutic target. Surgeon 6: 240-243, 2008.
23. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE and Pauli KD: An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343-349, 1997. (Pubitemid 27051604)
24. Zhang CC, Yang JM, Bash-Babula J, White E, Murphy M, Levine AJ and Hait WN: DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule- associated protein 4. Cancer Res 59: 3663-3670, 1999. (Pubitemid 29381870)
25. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B and Papadopoulos N: A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 106: 3964-3969, 2009.
26. Robinson M, Jiang P, Cui J, Li J, Wang Y, Swaroop M, Madore S, Lawrence TS and Sun Y: Global genechip profiling to identify genes responsive to p53-induced growth arrest and apoptosis in human lung carcinoma cells. Cancer Biol Ther 2: 406-415, 2003.
27. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B and Thompson CB: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752, 2007. (Pubitemid 47105521)
28. 2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88: 956-965, 1996. (Pubitemid 26239383)
29. Rowley R, Hudson J and Young PG: The wee1 protein kinase is required for radiation-induced mitotic delay. Nature 356: 353-355, 1992.
30. Mizuarai S, Yamanaka K, Itadani H, Arai T, Nishibata T, Hirai H and Kotani H: Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Weel inhibitor. Mol Cancer 8: 34, 2009.
31. 2 checkpoint and induces apoptosis. Cancer Biol Ther 3: 305-313, 2004.
32. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB and Hemann MT: The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 23: 1895-1909, 2009.
33. Mizuarai S, Yamanaka K and Kotani H: Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res 66: 6319-6326, 2006.
34. Baldwin A, Grueneberg DA, Hellner K, Sawyer J, Grace M, Li W, Harlow E and Munger K: Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc Natl Acad Sci USA 107: 12463-12468, 2010.
35. Kumar R, Gururaj AE and Barnes CJ: p21-activated kinases in cancer. Nat Rev Cancer 6: 459-471, 2006.
36. Reinhardt HC, Aslanian AS, Lees JA and Yaffe MB: p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11: 175-189, 2007.
37. Bauzon F and Zhu L: Racing to block tumorigenesis after pRb loss: An innocuous point mutation wins with synthetic lethality. Cell Cycle 9: 2118-2123, 2010.
38. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H and Sawyers CL: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98: 10314-10419, 2001.
39. Dong Y, Li A, Wang J, Weber JD and Michel LS: Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res 70: 5465-5474, 2010.
40. Michiue H, Eguchi A, Scadeng M and Dowdy SF: Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol Ther 8: 2306-2313, 2009.
41. Hulleman E and Helin K: Molecular mechanisms in gliomagenesis. Adv Cancer Res 94: 1-27, 2005.
42. Potratz JC, Saunders DN, Wai DH, Ng TL, McKinney SE, Carboni JM, Gottardis MM, Triche TJ, Jürgens H, Pollak MN, Aparicio SA and Sorensen PH: Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res 70: 8770-8781, 2010.
43. Meyer N and Penn LZ: Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990, 2008.
44. Pelengaris S, Khan M and Evan G: c-MYC: more than just a matter of life and death. Nat Rev Cancer 2: 764-776, 2002.
45. Clausen DM, Guo J, Parise RA, Beumer JH, Egorin MJ, Lazo JS, Prochownik EV and Eiseman JL: In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther 335: 715-727, 2010.
46. Maclean KH, Dorsey FC, Cleveland JL and Kastan MB: Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 118: 79-88, 2008.
47. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL and Quon KC: Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 5: 501-512, 2004.
48. Rottmann S, Wang Y, Nasoff M, Deveraux QL and Quon KC: A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc Natl Acad Sci USA 102: 15195-21500, 2005.
49. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R and Magrath I: Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 5: 56-61, 1993. (Pubitemid 23261519)
50. Gregory MA and Hann SR: c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 20: 2423-2435, 2000. (Pubitemid 30152050)
51. Welcker M and Clurman BE: FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8: 83-93, 2008. (Pubitemid 351161321)
52. Goga A, Yang D, Tward AD, Morgan DO and Bishop JM: Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 13: 820-827, 2007. (Pubitemid 47038193)
53. Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R and Caron HN: Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci USA 106: 12968-12973, 2009.
54. Yang D, Liu H, Goga A, Kim S, Yuneva M and Bishop JM: Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci USA 107: 13836-13841, 2010.
55. den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer M, Graf N, Scheerer M, Hall MA, Goga A, von Bubnoff N, Duyster J, Peschel C, Cleveland JL, Nilsson JA and Keller U: Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 116: 1498-1505, 2010.
56. Kaelin WG: Von Hippel-Lindau disease. Annu Rev Pathol 2: 145-173, 2007.
57. Kaelin WG Jr and Maher ER: The VHL tumour-suppressor gene paradigm. Trends Genet 14: 423-426, 1998.
58. Sutphin PD, Chan DA, Li JM, Turcotte S, Krieg AJ and Giaccia AJ: Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells. Cancer Res 67: 5896-5905, 2007. (Pubitemid 46985025)
59. Turcotte S, Sutphin PD and Giaccia AJ: Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: a novel molecule that induces autophagic cell death. Autophagy 4: 944-946, 2008.
60. Chan DA and Giaccia AJ: Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics. Cell Cycle 7: 2987-2990, 2008.
61. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J and Sawyers CL: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127, 2006. (Pubitemid 43050086)
62. -/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA 105: 16484-16489, 2008.
63. Annunziata CM and O'Shaughnessy J: Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res 16: 4517-4526, 2010.
64. Helleday T, Petermann E, Lundin C, Hodgson B and Sharma RA: DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8: 193-204, 2008. (Pubitemid 351301852)
65. Tutt A and Ashworth A: The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 8: 571-576, 2002.
66. Wu L: Wrestling off RAD51: a novel role for RecQ helicases. Bioessays 30: 291-295, 2008.
67. Lord CJ and Ashworth A: Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 8: 363-369, 2008.
68. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH and Poirier GG: PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10: 293-301, 2010.
69. Shrivastav M, De Haro LP and Nickoloff JA: Regulation of DNA double-strand break repair pathway choice. Cell Res 18: 134-147, 2008.
70. Martin SA, Lord CJ and Ashworth A: Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res 16: 5107-5113, 2010.
71. Jiricny J: The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 7: 335-346, 2006.
72. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC and Ashworth A: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921, 2005.
73. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917, 2005. (Pubitemid 40559005)
74. Chen S and Parmigiani G: Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25: 1329-1333, 2007.
75. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH and de Bono JS: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134, 2009.
76. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M and Tutt A: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376: 245-251, 2010.
77. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M and Carmichael J: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235-244, 2010.
78. Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW and Carey LA: Poly(ADP-Ribose) polymerase inhibition: 'Targeted' therapy for triple-negative breast cancer. Clin Cancer Res 16: 4702-4710, 2010.
79. Lark AL, Livasy CA, Dressier L, Moore DT, Millikan RC, Geradts J, Iacocca M, Cowan D, Little D, Craven RJ and Cance W: High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol 18: 1289-1294, 2005. (Pubitemid 41348647)
80. Cleator S, Heller W and Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol 8: 235-244, 2007. (Pubitemid 46291713)
81. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P and Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
82. Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, Jones C, Lord CJ, Vatcheva R, Rodriguez-Pinilla SM, Palacios J, Ashworth A and Reis-Filho JS: An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 121: 575-589, 2010.
83. Turner N, Tutt A and Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4: 814-819, 2004.
84. Rehman FL, Lord CJ and Ashworth A: Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 7: 718-724, 2010.
85. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, Orr N, Parton M, Smith IE, Reis-Filho JS, Dowsett M, Ashworth A and Turner NC: A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 16: 6159-6168, 2010.
86. Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ and Curtin NJ: Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 16: 2344-2351, 2010.
87. Martin SA, McCarthy A, Barber LJ, Burgess DJ, Parry S, Lord CJ and Ashworth A: Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 1: 323-337, 2009.
88. Martin SA, McCabe N, Mullarkey M, Cummins R, Burgess DJ, Nakabeppu Y, Oka S, Kay E, Lord CJ and Ashworth A: DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 17: 235-248, 2010.
89. de Souza-Pinto NC, Mason PA, Hashiguchi K, Weissman L, Tian J, Guay D, Lebel M, Stevnsner TV, Rasmussen LJ and Bohr VA: Novel DNA mismatch-repair activity involving YB-1 in human mitochondria. DNA Repair 8: 704-719, 2009.
90. Duval A and Hamelin R: Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res 62: 2447-2454, 2002. (Pubitemid 34462716)
91. Imai K and Yamamoto H: Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29: 673-680, 2008. (Pubitemid 351494153)
92. Popat S, Hubner R and Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23: 609-618, 2005. (Pubitemid 46224239)
93. Hewish M, Lord CJ, Martin SA, Cunningham D and Ashworth A: Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol 7: 197-208, 2010.
94. Lynch HT, Lynch JF, Lynch PM and Attard T: Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. Fam Cancer 7: 27-39, 2008.
95. Martin SA, Hewish M, Sims D, Lord CJ and Asworth A: Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res 71: 1836-1848, 2011.
96. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ and Ashworth A: Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1: 315-322, 2009.
97. Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L, Mansukhani M, Murty VV, Gaciong Z, Meek SE, Piwnica-Worms H, Hibshoosh H and Parsons R: Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7: 193-204, 2005.
98. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP and Yin Y: Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128: 157-170, 2007. (Pubitemid 46048887)
99. Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, Lakshman M, Gottipati P, Oliver FJ, Helleday T, Hammond EM and Bristow RG: Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 70: 8045-8054, 2010.
100. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, Bristow RG, Classon MK and Glazer PM: Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 65: 11597-11604, 2005.
101. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, Belmaaza A, Wouters B and Bristow RG: Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 68: 605-614, 2008.
102. Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM and Bristow RG: Hypoxia down-regulates DNA double-strand break repair gene expression in prostate cancer cells. Radiother Oncol 76: 168-176, 2005. (Pubitemid 41725444)
103. Ashworth A: Drug resistance caused by reversion mutation. Cancer Res 68: 10021-10023, 2008.